PUSH FOR RFID
FDA held a public workshop in early February to examine the progress made over the last two years in implementing electronic track-and-trace technologies, based on a radio frequency identification system (RFID). This initiative arose from the Prescription Drug Marketing Act of 1987 (PDMA), which aimed to combat drug counterfeiting by requiring "unauthorized wholesalers" to provide purchasers with a statement (a.k.a. pedigree) presenting a history of prior sales of the drug and the names and addresses of parties to these transactions. The legislation also required states to license wholesale drug distributors and curbed drug sampling. Those provisions were implemented years ago, but industry convinced FDA that a paper pedigree system would be costly and cumbersome. FDA agreed to delay implementation until manufacturers, distributors, and pharmacists could develop a workable approach.By 2004, the solution appeared to lie in an RFID tracking system. An FDA Counterfeit Drug Task Force issued a report that reviewed recent technological and policy developments and concluded that the agency should postpone the pedigree requirement once more to provide time to implement an electronic tracking system by 2007.
One problem is that manufacturers, wholesalers, and pharmacists disagree on how best to address these issues. Drug and biotech companies want FDA to implement the pedigree policy as a way to pressure all parties to move forward, while leaving the door open to the development of tracking technologies besides RFID.
Wholesalers and retail pharmacists insist that any national drug pedigree system has to be electronic. Distributors want FDA to phase in an RFID system utilizing electronic product codes (EPC), allowing enough time to develop needed data management and sharing processes. The National Association of Chain Drug Stores would like the agency to clarify that pedigrees apply only to parties outside the "normal distribution chain."
FDA and industry are under pressure to act as a growing number of states adopt their own drug pedigree requirements. Florida enacted a law in 2003 to discourage drug counterfeiting and diversion by requiring wholesalers to provide paper pedigrees for prescription drugs; it becomes fully effective in July 2006. California expects to implement a drug pedigree policy in 2007 or 2008 that establishes an electronic tracking system able to transmit extensive product data on all drugs.
Members of Congress also are introducing legislation establishing a time frame for phasing in electronic tracking of prescription drugs. One bill requires RFID tracking of the 30 most frequently counterfeited drugs (to be determined by FDA) by December 31, 2007. Another goes even further in requiring paper pedigrees until RFID technology is fully established.